CRISPR gene editing works by cutting DNA — introducing a double-strand break at a specific location, then relying on the cell's repair machinery to insert, delete, or modify the sequence. The cut is the mechanism. Every application inherits the risks of cutting: off-target breaks, unintended rearrangements, and permanent changes to the genome that cannot be undone.
Published in Nature Communications, researchers at UNSW Sydney developed a CRISPR system that turns silenced genes back on without cutting DNA at all. Instead of targeting the DNA sequence, the system targets methyl groups — chemical tags attached to the DNA that suppress gene expression. Removing these tags reactivates the gene without altering the underlying sequence. The genome is unchanged; only its packaging is modified.
The structural insight is about the distinction between the code and its regulation. Conventional CRISPR treats the DNA sequence as the target — the information is in the letters, and editing means changing them. Epigenetic editing treats the marks on the sequence as the target — the information is in the annotations, and editing means erasing them. The gene was never broken; it was silenced. The disease caused by a silenced gene does not require fixing the gene. It requires removing the silencer. This inverts the therapeutic logic: instead of rewriting the instruction, you remove the hand that covers it. The instruction was always there, waiting to be read. The obstruction was the disease.